Compare STTK & BCAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STTK | BCAL |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 538.3M | 578.3M |
| IPO Year | 2020 | 2020 |
| Metric | STTK | BCAL |
|---|---|---|
| Price | $6.10 | $19.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $10.00 | ★ $20.67 |
| AVG Volume (30 Days) | ★ 522.7K | 138.5K |
| Earning Date | 05-01-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 2.15% |
| EPS Growth | 53.02 | ★ 777.27 |
| EPS | N/A | ★ 0.42 |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.67 |
| P/E Ratio | ★ N/A | $45.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $14.07 |
| 52 Week High | $8.33 | $20.47 |
| Indicator | STTK | BCAL |
|---|---|---|
| Relative Strength Index (RSI) | 42.55 | 57.20 |
| Support Level | $5.85 | $18.62 |
| Resistance Level | $6.81 | $19.18 |
| Average True Range (ATR) | 0.52 | 0.36 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 23.03 | 72.87 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
California BanCorp is a registered bank holding company headquartered in San Diego, California. The Bank offers a range of financial products and services to individuals, professionals, and small to medium-sized businesses through its 14 branch offices and four loan production offices serving Northern and Southern California. The Bank's solutions-driven, relationship-based approach to banking provides accessibility to decision-makers and enhances value through partnerships with its clients. The company has one operating segment: Commercial Banking.